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Lipoprotein (a) (Lp[a]) represents a class of
lipoprotein particles having as a protein moiety
apolipoprotein B100 linked by a single disulfide
bridge to apolipoprotein (a) (apo[a]), a multikringle
structure with a close homology to plasminogen.1,2
A number of prospective and retrospective studies
have determined that Lp(a) is an independent risk
factor for atherosclerotic cardiovascular disease as a
function of the plasma levels of this lipoprotein.3-8
Plasma levels of Lp(a) have been shown to depend
mainly on hepatic synthesis9,10 and to a large extent
on apo(a) size, the smaller isoforms being associated
with higher levels of Lp(a) in the plasma.10
Coronary heart disease,5,6 cerebrovascular dis-
ease,11-13 and peripheral vascular disease14-16 have
all been linked to high plasma levels of Lp(a). The
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Purpose: An elevated plasma level of lipoprotein (a) is an independent risk factor for
atherothrombotic cardiovascular disease by yet undefined mechanisms. We have previ-
ously reported that matrix metalloproteinases cleave apolipoprotein (a) into 2 main frag-
ments, F1 and F2, the latter (the C-terminal domain) exhibiting in vitro a high-affinity
binding to extracellular matrix components, including fibrin(ogen). We therefore tested
the hypothesis that the lipoprotein (a) matrix metalloproteinase–derived F2 is localized
in potentially or morphologically unstable human carotid plaque at regions of increased
matrix metalloproteinase activity.
Methods: Carotid plaques removed after endarterectomy (n = 18) were evaluated for
structural features indicative of instability (thin fibrous cap, inflammation, and proxim-
ity of the necrotic core to the lumen); each plaque was classified as unstable (n = 10) or
stable (n = 8). Western blot analysis was performed to quantitate apolipoprotein (a) and
its fragments F1 and F2 in plaque extracts. Immunohistochemical staining was used to
localize apolipoprotein (a) and its fragments within the atherosclerotic plaque. In situ
zymography was used to determine regions of gelatinase (matrix metalloproteinase 2
and matrix metalloproteinase 9) activity.
Results: Western blot analyses demonstrated a 2.5-fold higher density of F2 in unstable
plaques than in stable plaques (3.07 ± 1.9 vs 1.18 ± 0.8; P < .05). In morphologically
unstable plaques, there was preferential distribution of F2 within regions of fibrous cap
inflammation and/or foam cell accumulation and within abluminal necrotic cores. In
morphologically stable plaques, however, localization was predominantly found in the
medial smooth muscle cells. Regions of enhanced matrix metalloproteinase 2 and matrix
metalloproteinase 9 activity co-localized with the transmural distribution of F2 within
the plaque.
Conclusions: These findings suggest that F2 in regions of increased matrix metallopro-
teinase activity is a potential mechanism for superimposed thrombotic events in mor-
phologically unstable human carotid plaques. The relationship between plasma lipopro-
tein (a) levels and accumulation of F2 and the potential correlation of F2 to human
plaque disruption and thrombosis warrant further study. (J Vasc Surg 2000;32:555-63.)
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positive correlation between disease and circulatory
Lp(a) levels has been corroborated by in vivo stud-
ies conducted in animal models.17-22
The premise that Lp(a) plays a causative role in
atherothrombotic disease is further supported by
studies in human and nonhuman primates demon-
strating that Lp(a) accumulates within walls of blood
vessels at sites prone to the development of athero-
sclerotic plaques and vascular injury.19-22 Studies by
Cushing et al,23 Rath et al,24 and Pepin et al25 have
shown that immunodetectable apo(a) is present in
human atherosclerotic lesions. The increased
atherothrombogenicity of Lp(a) may be attributed
in part to high-affinity interactions between certain
Lp(a) phenotypes and extracellular connective tissue
matrix components, such as proteoglycans,26,27
fibronectin,28 and fibrinogen.29 Pepin et al,25 for
example, demonstrated that a substantial portion of
apo(a) could not be readily extracted by physiologic
buffers; they attributed this phenomenon to the
superbinding effect of Lp(a).
More recent studies by Hoff et al30 showed
apo(a) that was extracted from human atherosclerot-
ic plaques to be fragmented; they attributed this frag-
mentation to oxidative events. Matrix metallopro-
teinases (MMPs) consist of a family of enzymes that
are considered to be a major pathway of extracellular
matrix degradation31 and to play a significant role in
the processes of atherogenesis and vascular injury.
Only recently, a relationship between MMPs and
Lp(a) has emerged from the studies of Edelstein et
al,32 which showed that some MMPs cleave Lp(a)
and apo(a) into two major fragments, F1 and F2—
the N- and C-terminal domains, respectively.
It has been demonstrated that F2, but not F1,
exhibits all of the properties of full-length apo(a)
tested thus far and therefore has a greater
atherothrombogenic potential.33 Thus, Lp(a)/apo-
(a) function may be modulated by factors that
increase the production of MMPs and/or enhance
the conversion of these enzymes from the inactive
(zymogen) to the active form. Transcriptional acti-
vation of MMPs may occur under the action of
cytokines (ie, interleukin 1, tumor necrosis factor α,
and platelet-derived growth factor) generated by
inflammatory cell infiltrates that both underlie
atherogenesis and neoplaque formation34 and pro-
mote the conversion of plasminogen to plasmin.35
The objective of this study was to determine
whether the F2 fragment is associated with human
carotid plaque instability. Unstable plaques exhibit
structural features antecedent to fibrous cap disrup-
tion and thromboembolic events and are more like-
ly to produce symptoms. In addition, we sought to
test the hypothesis that higher levels and specific
localization of F2 within the plaque are secondary to
enhanced MMP activity. In these experiments, fresh
carotid endarterectomy specimens were used to
quantitate F2 and its co-localization with MMP
activity in stable and unstable plaques, with an
emphasis on MMP-2 and MMP-9.
METHODS
Carotid endarterectomy specimens. Specimens
were obtained from 18 patients (9 men and 9
women) who underwent carotid endarterectomy for
treatment of high-grade carotid stenosis (70% or
greater) based on duplex ultrasound scan criteria.
Carotid endarterectomy was performed for sympto-
matic disease in five instances and in 13 patients with
asymptomatic disease. The symptoms included
amaurosis fugax in 2 patients, transient ischemic
attack in 2 patients, and cerebrovascular accident in
1 patient. All plaques in this study exhibited high-
grade stenosis, defined as 80% to 99% by duplex scan
criteria, with the exception of one “unstable
plaque,” which was classified as 50% to 79%.
Plaques were endarterectomized through use of
a standard open technique or eversion of the plaque
specimen. The harvested specimen included the dis-
tal common carotid artery in continuity with the
bifurcation and its extensions into the external and
internal branches. Harvested plaques were carefully
examined for disruptions related to operative
manipulation by an experienced angiopathologist
(S. G.).
Each fresh endarterectomy specimen was rinsed
in ice-cold saline solution. On removal of the
plaque, the specimen was immediately delivered to
the histopathologic laboratory and sectioned per-
pendicular to the axial centerline of the common
and internal carotid artery segments. Two consecu-
tive 2-mm segments were obtained from the region
of the internal carotid artery that grossly demon-
strated the greatest degree of lumen stenosis. One
segment was used for protein extraction (Western
blot analysis) and the other for histopathology, in
situ hybridization, and immunohistochemistry.
Histopathologic analysis. For histopathology,
each carotid segment was double-embedded in
paraffin, sectioned at 5 µm, and stained with hema-
toxylin and eosin and by the Gomori trichrome alde-
hyde fucshin and Weigert von Gieson procedures for
distinguishing connective tissue fibers and cells.
Sections were examined to characterize histologic
features of instability versus stability. Specifically,
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unstable plaques are characterized by proximity of
the necrotic core to the overlying fibrous cap and
lumen. Unstable plaques also appear to have a
greater degree of macrophage infiltration in and
about the fibrous cap than do stable plaques, and
they are associated with fibrous cap thinning and
erosion, implicating an ongoing induction of plaque
formation and/or an inflammatory or immune-
mediated response as a factor of plaque instability.36
Criteria for classification of plaques in this study
were based on data from a previous study in our lab-
oratory.53 In this study, the necrotic core was twice
as close to the lumen in unstable plaques than in sta-
ble plaques (0.27 ± 0.3 mm vs 0.5 ± 0.5 mm; P <
.01); the numbers of macrophages were 1114 ±
1104 and 385 ± 622, respectively (P < .009), and
the minimal fibrous cap thickness was 0.2 ± 0.2 mm
for stable plaques and 0.4 ± 0.4 mm for unstable
plaques.53 In addition, it has been noted that rup-
tured plaques are infiltrated by foam cells represent-
ing neoplaque formation, especially in regions where
the fibrous cap is the thinnest.37-41 Stable plaques
possess morphologic features that include an intact
fibrous cap without evidence of disruptions, no neo-
plaque formation, and a necrotic core distant from
the lumen. For the purposes of this study, each
plaque was classified as unstable or stable, not as
symptomatic or asymptomatic. The rationale for
choosing this histopathologic criteria for plaque
assessment is based on the fact that unstable plaques
are not necessarily symptomatic when carotid
endarterectomy is performed. The occurrence of
plaque rupture and clinical ischemic events do not
necessarily coincide with or antedate operation, par-
ticularly when a relatively small number of carotid
plaques are being evaluated.
Western blotting. Western blot analyses were
performed to measure apo(a) and its fragment pro-
tein in the extracts of human atherosclerotic carotid
plaques. Frozen samples were extracted through use
of chilled glass homogenizers in ice-cold Tris buffer
containing 0.075 mol/L potassium acetate, 0.3
mol/L NaCl, 0.1 mol/L L-arginine, 10 mmol/L
ethylenediamine tetraacetic acid (EDTA), and 0.25%
Triton x-100 (Promega Corporation, Madison, Wis;
pH 4.2). Protein concentration of samples was mea-
sured by the Lowry method. In equal amounts, the
samples (50 µg/lane) were heated at 95°C for 5
minutes in sample buffer (94 mmol/L phosphate
buffer (pH 7.0), 1% sodium dodecylsulfate (SDS), 2
mol/L urea, and 3% β-mercaptoethanol); this was
followed by electrophoresis on 4% to 12% SDS-poly-
acrylamide gel (SDS-PAGE) under reducing condi-
tions. The gels were placed onto Immobilon-P
sheets (Millipore, Bedford, Mass) wetted with a
buffer containing 48 mmol/L Tris and 39 mmol/L
glycine (pH 8.9). Blotting was performed on a hor-
izontal semidry electroblot apparatus (Phamacia-
LKB, Piscataway, NJ) at 0.8-1 mA/cm2 for 45 min-
utes at room temperature. The blots were blocked in
phosphate-buffered saline solution (PBS) containing
5% nonfat dry milk and 0.3% Tween 20 (ICI
Atkemix, Brantford, Ontario); this was followed by
incubation with anti-apo(a) antibody (prepared in
our laboratory). The blots were washed and incu-
bated with antirabbit horseradish peroxidase-labeled
immunoglobulin G (IgG; Sigma, St Louis, Mo).
Subsequently, the blots were developed with ECL
Western Detection Reagent (Amersham Pharmacia
Biotech, Uppsala, Sweden) according to the manu-
facturer’s instructions. For the positive control,
Lp(a) was incubated with active MMP-9 (Chem-
icon, Temecula, Calif) at a ratio of 20:1, w/w
(Lp[a]: enzyme) at 37°C for 18 hours in 50
mmol/L Tris-HCl buffer containing 0.15 mol/L
NaCl, 10 mmol/L CaCl2, 0.02% Brij35 (Acros
Organics NV, Fairlawn, NJ), and 0.02% NaN3 (pH
7.6). The reaction was terminated with 50 mmol/L
EDTA and electrophoresed as described. The
immunostained bands after Western blotting were
quantitated through use of scanning densitometry
(Bio-Rad 620 scanner, Richmond, Calif).
Immunohistochemistry. Carotid plaques re-
moved at endarterectomy were embedded in O.C.T.
compound (Miles, Elkhart, Ind) and frozen in 2-
methylbutane cooled with dry ice. Frozen sections
of tissue were cut on a cryostat at 6-µm intervals
perpendicular to the direction of blood flow so that
the entire cross section appeared in each section.
The tissue sections were quenched with 0.6% H2O2
in methanol for 20 minutes and blocked with 10%
bovine serum albumin containing 1% Tween 20 in
PBS (PBS-T) for 1 hours. After being washed in
PBS-T, the sections were incubated with a mono-
clonal mouse antihuman F2 antibody at concentra-
tion of 50 µg/mL in a humid chamber overnight at
4°C. The sections were then washed in PBS-T and
incubated with peroxidase-conjugated rabbit anti-
mouse IgG at 1:200 dilution (Amersham). After 40
minutes of incubation at room temperature, the sec-
tions were washed in PBS-T and incubated with sub-
strate solution (0.05% 3,3’-diaminobenzidine in tap
water with 0.02% H2O2) for 5 minutes, then washed
in PBS buffer to stop the reaction. The slides were
stained with hematoxylin, dehydrated with graded
alcohol and xylene, and then mounted. Control sec-
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tions were performed with omission of primary anti-
bodies.
In situ zymography. Gelatin (Sigma) was fluo-
rescinated through use of a kit for fluorescent label-
ing (Boehringer, Mannheim, Germany), according
to the manufacturer’s instructions, to detect gelati-
nolytic activity (MMP-2 and MMP-9). Fluorescent
substrate (1 mg/mL) is mixed (1:1) with 1% agarose
melted in Tris-HCl (50 mmol/L, pH 7.4) contain-
ing 10 mmol/L CaCl2 and 0.05% Brij 35 (Tris
buffer). The liquid mixture was then smeared on
prewarmed glass slides. Frozen sections of unfixed
tissue were cut on a cryostat at 6 µm and applied on
top of the substrate film. A drop of the Tris buffer
was added over each tissue section and coverslipped.
Slides were incubated in a humidified chamber at
37°C for 24 hours. Lysis of the substrate was
assessed by examination under a fluorescent micro-
scope. The areas of enzymatic activity were repre-
sented as zones lacking fluorescence and therefore
appeared as black regions in the fluorescent sub-
strate films. Control sections were layered on glass
slides covered with substrates. A drop of Tris buffer
containing 20 mmol/L EDTA (an inhibitor of
MMPs) was applied on top of each section.
Data analysis. Quantitative differences in the
density of F2 between unstable and stable carotid
plaques were compared through use of paired
Student t test analysis. Data are expressed as means
± SEMs.
RESULTS
Clinical features and histopathologic analysis.
Of the 18 carotid endarterectomy plaques studied,
10 were classified as unstable, as defined by the
structural features indicative of disruption or plaque
instability. Eight plaques lacked these characteristics
and were characterized as stable. Of the 18 patients,
five underwent endarterectomy for symptomatic
carotid atherosclerosis and 13 for asymptomatic
severe carotid stenosis. Within the unstable plaque
group, two (20%) of 10 patients were symptomatic;
within the stable plaque group, three (37.5%) of
eight were symptomatic.
Western blot analyses. The proteins from rep-
resentative axial sections obtained from each unsta-
ble and stable plaque were extracted with Tris buffer,
as described in the Methods section, and subjected
to 4% SDS-PAGE immunoblot analysis through use
of a rabbit anti-apo(a) polyclonal antibody. Fig 1, A
shows the pattern of extracts obtained from plaques
of four endarterectomy subjects having stable (lanes
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Fig 1. Western blot analysis of plaque extracts and apo(a) after incubation with purified MMP-
9. Proteins from representative axial section obtained from each unstable and stable plaque
were extracted with Tris buffer, as described, and subjected to 4% SDS-PAGE immunoblot
analysis through use of rabbit anti-apo(a) polyclonal antibody. A, Pattern of extracts obtained
from endarterectomy subjects having stable (lanes 1 and 2) and unstable (lanes 3 and 4)
plaques. Lane 5 shows digestion pattern of apo(a) after limited in vitro proteolysis with MMP-
9; both F1 and F2 are present. Extracts from both stable and unstable plaques exhibit band
migrating in position of F2. Band corresponding to F1 appeared only in unstable plaques and
in minor amounts (lanes 3 and 4). Only stable plaques exhibited apo(a) staining band (lanes 1
and 2). B, Quantitative densitometry. Extract from unstable plaques shows 2.5-fold increase
of F2 band in comparison with stable plaques (*P < .05). Arrows show migrating positions of
apo(a) and its fragments F1 and F2. Numbers indicate molecular weights.
A B
1 and 2) and unstable (lanes 3 and 4) plaques. For
reference, lane 5 shows the digestion pattern of
apo(a) after limited in vitro proteolysis with MMP-
9; both F1 and F2 are present. We chose not to
include MMP-2 as a positive control because of data
from the laboratory of one of the authors (A. M. C.)
that showed apo(a) digestion by MMP-2 to be
exactly identical to apo(a) digestion by MMP-9.
Only MMP-9 data were presented to avoid redun-
dancy. Extracts from both stable and unstable
plaques exhibited a band migrating in the position of
F2. However, on the basis of quantitative densitom-
etry (Fig 1, B), the extract from the unstable plaques
demonstrated a 2.5-fold increase of this band in
comparison with the extract from the stable plaques
(3.1 ± 1.9 vs 1.2 ± 0.8; P < .05). A band corre-
sponding to F1 appeared only in the unstable
plaques and in minor amounts (lanes 3 and 4). Of
note, only the stable plaques exhibited an apo(a)
staining band (lanes 1 and 2).
Immunohistochemistry studies. To determine
the relative location of F2 within the carotid plaque,
we performed immunohistochemistry on the unsta-
ble and stable plaques using a monoclonal antibody
specific for F2. Unstable and stable plaques demon-
strated a differential distribution of F2. Specifically,
F2 was concentrated in the abluminal lipid core (Fig
2, A) and fibrous cap (Fig 2, C) of the unstable
plaques. In contrast, F2 localized within the more
medial smooth muscle cells in the stable plaques (Fig
3, A). These findings may suggest an association
between the spatial distribution of key histomorpho-
metric features of plaque instability (ie, proximity of
the necrotic core to the fibrous cap) and the local-
ization of the F2 molecule.
In situ zymography. To identify regions of
gelatinolytic activity in unstable and stable carotid
plaques we performed in situ zymography to deter-
mine the distribution of MMP-2 and MMP-9. Both
MMP-2 activity and MMP-9 activity were enhanced
in regions in which F2 was present. Specifically,
MMP-2 and MMP-9 activity was concentrated in
the abluminal lipid core and fibrous cap in unstable
plaques (Figs 2, B and D); in contrast, there was a
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Fig 2. Co-localization of apo(a) fragment F2 and in situ gelatinolytic activity in unstable plaque.
Immunostaining of F2 is concentrated in abluminal lipid core (A) and fibrous cap (C) of these
plaques. In situ zymography reveals enhanced gelatinolytic activity (black dots) at regions of F2
localization (B and D; original magnification ×25). LC, Lipid core; FC, fibrous cap.
A B
C D
greater distribution within the medial smooth mus-
cle cells in stable plaques (Fig 3, B). The similar dis-
tribution of MMP activity and F2 localization with-
in unstable and stable human carotid plaques sup-
ports an association between MMP activity and
apo(a) fragmentation.
DISCUSSION
Although the association of Lp(a) with an
increased incidence of atherosclerotic cardiovascular
disease has been acknowledged for more than 25
years, little is known of the fate Lp(a) when it reach-
es the intima of an atheromatous artery but that it is
localized within the plaque. The results of the 
present investigation now provide evidence that
apo(a) undergoes fragmentation and that one of the
fragments, F2, accumulates to a greater degree than
F1 in unstable carotid plaques. The results of the
immunochemical analyses also indicate that F2 is
distributed in proximity to the fibrous cap within the
area of plaque disruption. These findings are consis-
tent with those in vitro by Edelstein et al33 and
Klezovitch et al27 showing that in comparison with
F1, F2 preferentially binds to members of the vascu-
lar extracellular matrix–fibrinogen, fibronectin, and
the protein core of proteoglycans. Those previous
data and the present findings invite the suggestion
that F2 is the pivotal determinant of apo(a) patho-
genicity and a potential contributor to the throm-
botic event attending the disruption of the athero-
sclerotic plaque.
The mechanism or mechanisms underlying the
cardiovascular pathogenicity of Lp(a) are still largely
undetermined. The difficulty relates in part to the
structural complexity of Lp(a) and in part to limited
knowledge concerning the fate of this lipoprotein
when it transfers from the plasma into the artery
wall. Apo(a), the key component of Lp(a), although
homologous in some aspects to plasminogen, differs
from it in a number of structural features in terms of
both kringles and the linkers between these kringles.
The linkers, which are highly glycosylated, not only
serve to maintain the kringles in the appropriate
alignment needed for their function but also are the
sites of cleavage by enzymes of biologic relevance,
such as those of the elastase and metalloproteinase
families, that can be operative at the level of the arte-
rial wall.
Another novel finding in our current study was
the co-localization in the unstable plaque of F2 with
the 2 tested MMPs, MMP-2 and MMP-9. This sug-
gests, on the basis of our previous observations,32
that enzymes of the MMP family are involved in
apo(a) fragmentation within the inflammatory
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A B
Fig 3. Co-localization of apo(a) fragment F2 and in situ gelatinolytic activity in stable plaque.
Immunostaining of F2 is concentrated within more medial smooth muscle cells in these
plaques (A). In situ zymography reveals enhanced gelatinolytic activity (black dots) at regions
of F2 localization (B; original magnification ×25).
milieu of the atheromatous lesion. According to this
premise, factors that regulate the activation of
MMPs—inflammatory cytokines, plasmin, trans-
forming growth factor-β (TGF-β), and others—
would also regulate the generation of apo(a) frag-
ments and thus their cardiovascular pathogenicity.
This hypothesis would explain why there is essential-
ly no immunodetectable apo(a) in nonlesion areas.
The proposed notion that accumulation of F2
resulting from an MMP-mediated inflammatory
process is an important event in Lp(a) pathogenicity
raises mechanistic questions for which only specula-
tive hypotheses can be provided at this time. Given
the previous observations by Loscalzo et al,44 who
used whole Lp(a), F2 may compete for the binding
of plasminogen to the fibrin surface, the result being
a retardation or prevention of plasmin generation
and thus impaired fibrinolysis. Moreover, our recent
in vitro findings that F2 binds avidly to the protein
core of the proteoglycan decorin and biglycan, both
abundant in arterial lesions,33 raise the possibility
that as a consequence of this binding the MMP-
dependent degradation of these proteoglycans may
decrease, favoring their accumulation in the suben-
dothelial intima of the arterial wall. These hypothe-
ses are testable and invite systematic studies aimed at
relating inflammation, factors modulating MMP
activation, and plasmin generation to the production
of apo(a) fragments and the assessment of their spe-
cific cardiovascular pathogenicity.
Although it is difficult to define from human
plaque analyses a mechanistic relationship in terms of
which (1) apo(a) and its fragments modulate plaque
MMP activity by way of attenuating the plasmin path-
way or (2) existing plaque MMP activity, as induced
by inflammatory cytokines, is a prerequisite for apo(a)
thrombogenecity, several hypotheses have been pro-
posed as to the temporal sequence of molecular events
involving MMPs, plasminogen regultion, and TGF-β.
Studies in cell culture have shown that Lp(a) com-
petes for the binding of plasminogen to the “plas-
minogen receptor” of endothelial cells45 and
macrophages.46 Such a competitive effect has also
been shown to occur in microtiter plates.35 The dis-
placed plasminogen, being no longer surface-bound,
would become less competent for activation by tissue
plasminogen activator; as a consequence, the genera-
tion of plasmin is decreased, as is fibrinolysis.47
However, these events have not yet been demonstrat-
ed in the arterial wall. There is some experimental evi-
dence that Lp(a)-mediated depressed generation of
plasmin may have atherothrombogenic implications.
As previously described, MMPs are considered to
be a major pathway of extracellular matrix degrada-
tion48 and to play a significant role in the processes
of atherogenesis and vascular injury. Thus,
Lp(a)/apo(a) function may be modulated by factors
that increase the production of MMPs and/or
enhance the conversion of these enzymes from the
inactive (zymogen) to the active form. Transcrip-
tional activation of MMPs may occur under the
action of cytokines (ie, interleukin 1, tumor necrosis
factor α, and platelet-derived growth factor) during
the underlying inflammation that characterizes the
atherosclerotic process.32 In turn, plasmin and
TGFβ can activate latent MMPs in vitro and proba-
bly perform this function in vivo.34,48 Lee et al31
have also demonstrated that plasmin may play an
important role in the secretion of MMPs. Knowledge
of the degree of plasmin generation in the athero-
sclerotic plaque, as determined by tissue plasmino-
gen activator, plasminogen-activator inhibitor-1,
plasminogen receptor, and plasmin in plaque extract
measurements, should prove very useful in establish-
ing the mechanisms underlying cardiovascular path-
ogenicity of Lp(a) and its derivatives and their influ-
ence on plaque homeostasis.
An inherent limitation of this investigation is the
small number of carotid plaques studied. This may
provide a partial explanation for the similar numbers
of clinically symptomatic and asymptomatic patients
with histopathologically defined stable and unstable
plaques. Furthermore, on the basis of previous stud-
ies of asymptomatic and symptomatic critical
stenoses, the degree of plaque complexity and pre-
disposition to potential complications appear to be
related to plaque burden and degree of luminal
stenosis. Thus, patients with features of plaque insta-
bility might simply not yet be symptomatic.49-51 An
additional concern regarding this study is the semi-
quantitative nature of the densitometric analysis.
Further studies will be necessary to reinforce the
results of this preliminary work. Finally, although
the atherogenic role of Lp(a) levels is controver-
sial,17,18,28 we are at present studying the relation-
ship between Lp(a) levels/isoforms and localization
of apo(a) fragments in human plaques. It is our con-
tention, however, that cleavage of apo(a) into high-
affinity thrombogenic fragments is contingent on
metalloproteinase activity of the plaque rather than
on level or molecular weight of the Lp(a) substrate.
In summary, our current findings provide new
insight into the potential relationship between MMP
activity, apo(a) fragmentation, and plaque biology.
This insight is consonant with current views on the
inflammatory basis of the atherothrombotic process.52
JOURNAL OF VASCULAR SURGERY
Volume 32, Number 3 Fortunato et al 561
REFERENCES
1. McLean JW, Tomlinson JE, Kuang W, et al. cDNA sequence
of human apolipoprotein(a) is homologous to plasminogen.
Nature 1987;330:132-7.
2. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly
WS, Valle D, editors. The metabolic and molecular basis of
inherited disease, 1887-1912. New York: McGraw Hill; 1995.
3. Orth-Gomer K, Mittleman MA, Schenk-Gustafson K, et al.
Lipoprotein(a) as a determinant of coronary heart disease in
young women. Circulation 1997;95:329-34.
4. Hoefler G, Harnoncourt F, Paschke E, Mirti W, Pfeiffer KH,
Kostner GM. A risk factor for myocardial infarction.
Arteriosclerosis 1988;8:398-401.
5. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg
AL. Lp(a) lipoprotein as a risk factor for myocardial infarc-
tion. JAMA 1986;256:2540-4.
6. Budde T, Fechtrup C, Bosenberg E, et al. Plasma lp(a) levels
correlate with number, severity, and length-extension of
coronary lesions in male patients undergoing coronary arte-
riography for clinically suspected coronary atherosclerosis.
Arterioscler Thromb 1994;14:1730-6.
7. Kario K, Matsuo T, Imiya M, et al. Close relation between
lipoprotein (a) levels and atherothrombotic disease in
Japanese subjects > 75 years of age. Am J Cardiol
1994;73:1187-90.
8. Parlavecchia M, Pancaldi A, Taramelli R, et al. Evidence that
apolipoprotein(a) phenotype is a risk factor for coronary
artery disease in men ≤ 55 years of age. Am J Cardiol
1994;74:346-51.
9. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB. Variation
in lipoprotein(a) concentrations among individuals with the
same lipoprotein(a) isoform is determined by the rate of
lipoprotein(a) production. J Clin Invest 1993;91:443-7.
10. Rader DJ, Cain W, Ikewaki K, et al. The inverse association
of plasma lipoprotein(a) concentrations with apolipopro-
tein(a) isoform size is not due to differences in Lp(a) catabo-
lism but to differences in production rate. J Clin Invest
1994;93:2758-63.
11. Bolger C, Phillips J, Gilligan S, et al. Elevated levels of
lipoprotein (a) in association with cerebrovascular saccular
aneurysmal disease. Neurosurgery 1995;37:241-5.
12. Shintan S, Kikuchi S, Hamaguchi H, Shiigai T. High serum
lipoprotein(a) levels are an independent risk factor for cere-
bral infarction. Stroke 1993;24:965-9.
13. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein(a) and
ischemic cerebrovascular disease in young adults. Stroke
1994;25:74-8.
14. Bandello F, Vigano D’Angelo S, Parlavecchia M, et al.
Hypercoagulability and high lipoprotein(a) levels in patients
with central retinal vein occlusion. Thromb Haemost
1994;72:39-43.
15. Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp(a)
lipoprotein is an independent, discriminating risk factor for
premature peripheral atherosclerosis among white men. Arch
Intern Med 1994;154:801-6.
16. Groves P, Rees A, Bishop A, et al. Apolipoprotein(a) concen-
trations and susceptibility to coronary artery disease in
patients with peripheral vascular disease. Br Heart J
1993;69:26-30.
17. Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein
(a) serum concentration and apolipoprotein (a) phenotype
correlate with severity and presence of ischemic cerebrovascu-
lar disease. Stroke 1995;26:1841-8.
18. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R,
Patsch W. The relation of lipoprotein (a) concentrations and
apolipoprotein (a) phenotypes with asymptomatic atheroscle-
rosis in subjects of the atherosclerosis risk in communities
(ARIC) study. Arterioscler Thromb 1993;13:1558-66.
19. Angles-Cano E. Structural basis for the pathophysiology of
lipoprotein (a) in the athero-thrombotic process. Braz J Med
Biol Res 1997;30:1271-80.
20. Kusumi Y, Scanu AM, McGill HC, Wissler RW. Athero-
sclerosis in a rhesus monkey with genetic hypercholes-
terolemia and elevated plasma Lp(a). Atherosclerosis 1993;
99:165-74.
21. Ryan MJ, Emig LL, Hicks GW, et al. Localization of lipopro-
tein(a) in a monkey model of rapid neointimal growth.
Arterioscler Thromb Vasc Biol 1997;17:181-7.
22. Nielsen LB, Gronholdt MLM, Schroeder TV, Stender S,
Nordestgaard BG. In vivo transfer of lipoprotein(a) into
human atherosclerotic carotid arterial intima. Arterioscler
Thromb Vasc Biol 1997;17:905-11.
23. Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and
localization of apolipoproteins(a) and B in coronary artery
bypass vein grafts resected at reoperation. Arteriosclerosis
1989;593:603.
24. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J,
Beisiegel U. Detection and quantification of lipoprotein(a) in
the arterial wall of 107 coronary bypass patients. Arterio-
sclerosis 1989;9:579-92.
25. Pepin JM, Oneil JA, Hoff HF. Quantification of apo(a) and
apoB in human atherosclerotic lesions. J Lipid Res
1991:32:317-27.
26. Bihari-Varga M, Gruber E, Rothenden M, Zechner R,
Kostner GM. Interaction of lipoprotein(a) and low density
lipoprotein with glycosaminoglycans from human aorta.
Arteriosclerosis 1988;8:851-7.
27. Klezovitch O, Edelstein C, Scanu AM. Apolipoprotein(a)
binds via its C-terminal domain to the protein core of the
proteoglycan decorin. J Biol Chem 1998;273:23856-65.
28. Edelstein C, Italia JI, Scanu AM. Polymorphonuclear cells
isolated from human peripheral blood cleave Lp(a) and
apo(A) at multiple interkringle sites via the enzyme elastase:
generation of miniLp(a) particles and apo(a) fragments. J
Biol Chem 1997;272:11079-87.
29. Salonen E-M, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C.
Lipoprotein(a) binds to fibronectin and has serine proteinase
activity capable of cleaving it. EMBO J 1989;8:4035-40.
30. Hoff HF, Oneil J, Smejkal GB, Yashiro A. Immunochemically
detectable lipid-free apo(a) in plasma and in human atheroscle-
rotic lesions. Chem Phys Lipids 1994;67:271-80.
31. Lee RT, Libby P. The unstable atheroma. Arterioscler
Thromb Vasc Biol 1997;17:1859-67.
32. Edelstein C, Italia JA, Klezovitch O, Scanu AM.
Metalloproteinase-2 cleaves lipoprotein(a) in the linker
region between kringles IV-4 and IV-5. Circulation
1997;96(Suppl):I-111.
33. Edelstein C, Italia JI, Scanu AM. Polymorphonuclear cells
isolated from human peripheral blood cleave Lp(a) and
apo(A) at multiple interkringle sites via the enzyme elastase:
generation of miniLp(a) particles and apo(a) fragments. J
Biol Chem 1997;272:11079-87.
34. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expres-
sion of matrix metalloproteinases and matrix degrading activ-
ity in vulnerable regions of human atherosclerotic plaques. J
Clin Invest 1994;94:2493-503.
JOURNAL OF VASCULAR SURGERY
562 Fortunato et al September 2000
35. Snyder ML, Polacek D, Scanu AM, Fless GM. Comparative
binding and degradation of lipoprotein(a) and low density
lipoprotein by human monocyte derived macrophages. J Biol
Chem 1992;267:339-46.
36. Hennerici M, Trockel U, Rautenberg W, et al. Spontaneous
progression and regression of small carotid atheroma. Lancet
1985;22:1415-9.
37. Feely TM, Leen EJ, Colgan MP, et al. Histologic characteristics
of the carotid artery plaque. J Vasc Surg 1991;3:719-24.
38. Seeger JM, Klingman N. The relationship between carotid
plaque composition and neurologic symptoms. J Surg Res
1987;43:78-85.
39. Falk E. Why do plaques rupture? Circulation 1992;86(SIII):
30-42.
40. Mazzone A, DeServi S, Ricevuti G, et al. Increased expression
of neutrophil and monocyte adhesion molecules in unstable
coronary artery disease. Circulation 1993;88:358-63.
41. Lendon CL, Davies MJ, Born GVR, et al. Atherosclerotic
plaques are locally weakened when macrophage density is
increased. Atherosclerosis 1991;87:87-90.
42. Scanu AM, Atzeni M, Edelstein CE, Tonolo G, Maioli M,
Klezovitch O. Lipoprotein (a): identification of subjects with a
superbinding capacity for fibrinogen. Clin Genet 1998. In
press.
43. Hajjar KA, Gavish D, Breslow JL, Nachman RL.
Lipoprotein(a) modulation of endothelial cell surface fibri-
nolysis and its potential role in atherosclerosis. Nature
1989;339:303-5.
44. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein
(a), fibrin binding, and plasminogen activation. Arterio-
sclerosis 1990;10:240-5.
45. Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML.
Antifibrinolytic effect of recombinant apolipoprotein (a) in
vitro is primarily due to attenuation of tPA-mediated Glu-
plasminogen activation. Biochemistry 1995;18:5151-7.
46. Miles LA, Fless GM, Levine EG, Scanu AM, Plow EF. A
potential role for the thrombotic risks associated with
lipoprotein(a). Nature 1989;339:301-3.
47. Sangrar W, Baiza L, Nesheim ME, Koschinsky ML.
Antifibrinolytic effect of recombinant apolipoprotein (a) and
low density lipoprotein by human monocyte derived
macrophages. J Biol Chem 1992;267:339-46.
48. Masawa N, Glagov S, Zarins CK. Quantitative morphologic
study of intimal thickening at the human carotid bifurcation,
II: the compensatory enlargement response and the role 
of the intima in tensile support. Atherosclerosis 1994;
107:147-55.
49. Bassiouny HS, Davis H, Masawa N, et al. Critical carotid steno-
sis: morphologic and chemical similarity between symptomatic
and asymptomatic plaques. J Vasc Surg 1989;9:202-12.
50. Masawa N, Glagov S, Zarins CK. Quantitative morphologic
study of intimal thickening at the human carotid bifurcation,
I: axial and circumferential distribution of maximum intimal
thickening in asymptomatic uncomplicated plaques. Athero-
sclerosis 1994;107:137-46.
51. Glagov S, Masawa N, Bassiouny HS, et al. Morphologic basis
for establishing end-points for early plaque detection and
plaque stability. Int J Card Imaging 1995;4:1-7.
52. Ross R. Atherosclerosis: an inflammatory disease. N Engl J
Med 1999;340:115-28.
53. Bassiouny HS, Sakaguchi Y, Mikucki SA, et al. Juxtalumenal
location of plaque necrosis and neoformation in symptomatic
carotid stenosis. J Vasc Surgery 1997;26:585-94.
Submitted Sep 29, 1999; accepted Mar 2, 2000.
JOURNAL OF VASCULAR SURGERY
Volume 32, Number 3 Fortunato et al 563
